|
MURAGAKI Yoshihiro
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Visiting Professor |
|
| Article types | Other |
| Language | English |
| Peer review | Peer reviewed |
| Title | Genetic Analysis in Patients With Newly Diagnosed Glioblastomas Treated With Interferon-Beta Plus Temozolomide in Comparison With Temozolomide Alone |
| Journal | Formal name：Journal of neuro-oncology Abbreviation：J Neurooncol ISSN code：0167594X/15737373 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 148(1),pp.17-27 |
| Author and coauthor | NATSUME Atsushi†, AOKI Kosuke, OHKA Fumiharu, MAEDA Sachi, HIRANO Masaki, ADILIJIANG Alimu, MOTOMURA Kazuya, SUMI Minako, NISHIKAWA Ryo, NARITA Yoshitaka, MURAGAKI Yoshihiro, MARUYAMA Takashi, ITO Tamio, BEPPU Takaaki, NAKAMURA Hideo, KAYAMA Takamasa, SATO Shinya, NAGANE Motoo, MISHIMA Kazuhiko, NAKASU Yoko, KURISU Kaoru, YAMASAKI Fumiyuki, SUGIYAMA Kazuhiko, ONISHI Takanori, IWADATE Yasuo, TERASAKI Mizuhiko, KOBAYASHI Hiroyuki, MATSUMURA Akira, ISHIKAWA Eiichi, SASAKI Hikaru, MUKASA ,Akitake, MATSUO Takayuki, HIRANO Hirofum, KUMABE Toshihiro, SHINOURA Nobusada, HASHIMOTO Naoya, AOKI Tomokazu, ASAI Akio, ABE Tatsuya, YOSHINO Atsuo, ARAKAWA Yoshiki, ASANO Kenichiro, YOSHIMOTO Koji, SHIBUI Soichiro, OKUNO Yusuke, WAKABAYASHI Toshihiko, and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG) |
| Publication date | 2020/05/04 |
| Summary | Purpose: This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone.
Experimental: DESIGN: Of 122 tumors, we performed deep targeted sequencing to determine the somatic mutations, copy number variations, and tumor mutation burden; pyrosequencing for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation; Sanger sequencing for the telomerase reverse transcriptase (TERT) promoter; and microsatellite instability (MSI) testing in 95, 91, 91 and 72 tumors, respectively. We performed a multivariable Cox regression analysis using backward stepwise selection of variables including clinical factors (sex, age, performance status, residual tumor after resection, tumor location) and genetic alterations. |
| DOI | 10.1007/s11060-020-03505-9 |
| PMID | 32367437 |